TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-selected Walking Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Time Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Alarms
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Change in Clinical Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Annual Change in Total Kidney Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in child salivary cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Severity as Determined by IBS-SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of variance of walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reflection and Insight Scale (SRIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of chemotherapy-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of successful FeNO measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of MRI images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac extracellular matrix remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA <400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA >=400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in PN/IV Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in PN/IV Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Multidimensional Fatigue Inventory (MFI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Baseline in Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Self-reported Outcomes of Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Respiratory Failure-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Time to Breathing Room Air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the hypothalamic-pituitary adrenal (HPA) axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the hypothalamic-pituitary-gonadal (HPG) axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Presence of obstructive coronary artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motion accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic profile of culture media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in knee pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of Desidustat
Endpoint domain: Adverse events/effects
Primary endpoint: Trabecular bone structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food texture exposure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Textured food acceptance: scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic Accuracy of cIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gross Motor Functional Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of diagnostic procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Choroid and retinal thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of ITB Friction Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving WOMAC Pain Score Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Diastolic Blood Pressure and Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Pain intensity at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from QuickDASH questionnaire at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Pressure Pain Thresholds (PPT) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort score on the visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical complication
Endpoint domain: Adverse events/effects
Primary endpoint: Excessive rate of increase in sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative incidence of grade 3+ bowel perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of grade 3+ bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of grade 4+ nonhematologic acute adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of signed donor cards
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Short-term mortality due to bloodstream infection
Endpoint domain: Mortality/survival
Primary endpoint: Long-term mortality due to bloodstream infection
Endpoint domain: Mortality/survival
Primary endpoint: Long-term morbidity due to bloodstream infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of major renal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in cardiac output before anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in cardiac output after spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep Quality - Trouble Falling Asleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: DAS28 - Global Health (GH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAPID 3 - Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in auditory comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brain oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of True Positive/Negative aMMP-8 Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma Glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neonatal admission to intensive care unit within the first 24 hours
Endpoint domain: Mortality/survival
Primary endpoint: Patient Satisfaction regarding esthetic results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived efficacy in patient-physician interaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death for all causes
Endpoint domain: Mortality/survival
Primary endpoint: Urgent heart transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Indocyanine plasma disappearance rate (ICG-PDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bimanual Coordination accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study Objectives
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: lesion visualization criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with adequate thromboprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: myelosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrences of PCR-Confirmed Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Scar Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in volume of thoracoabdominal compartments during breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cognitive and memory function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transdermal Alcohol Concentration (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in Raynaud's Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of number of Raynaud's events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess safety: frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of immune-related colitis
Endpoint domain: Adverse events/effects
Primary endpoint: Marker of blood-brain dysfunction using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Markers of blood-brain dysfunction using CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sleep quality measurement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: preferences for medical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient self-reported BM data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at 30 days and 1-year
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change in PTH Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Bone Mineral Density (BMD) of the Femoral Neck by Dual-energy X-ray Absorptiometry (DXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change in Mean Hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nevirapine uptake in labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor vessel identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Disease-free Survival at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Disease-specific Survival at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Opioid use during study enrollment
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of vaginal atrophy symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: % superficial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in WOMAC Physical Function Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Global Assessment of Osteoarthritis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in Overall Target Plaque Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Thymic output improvement by TRECs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thymic output improvement by flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of cardiac and neurologic related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of vaso-occlusive pain crisis (VOC) resolution without complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of secondary acute chest syndrome (ACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Coping Self-Efficacy Scale (CSES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Post-Traumatic Stress Disorder Checklist-Military Version (PCL-M)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients who are symptom free by day four
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Treatment emergent Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PF-06648671 Plasma Area Under the Curve from Time Zero to 24 hour after dosing (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Clinician-Administered PTSD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in splenomegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Occurrence of all serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-PhtD antibody concentration in all vaccine groups
Endpoint domain: Physiological/clinical
Primary endpoint: Mean Change in Fasting Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with diagnosis of PTSD
Endpoint domain: Mortality/survival
Primary endpoint: Percent Alcohol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' Response to Survey Questions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance of the Swedscore colposcopy scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Barthel index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of cycles in six months of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Successful Smoking Cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ASL (Arterial spin labeling) based perfusion measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in The Self-Paced Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthesia success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of gingival anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal flora and pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyberg Child Behavior Inventory (ECBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child and Adolescent Trauma Screener (CATS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Stress Index Short Form 4th edition (PSI-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Dyadic Parent-Child Interaction Coding System
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Transcranial doppler ultrasound velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Course of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety based on vital sign evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety based on 12-lead ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety based on cardiac rhythm monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety based on routine lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of plerixafor
Endpoint domain: Adverse events/effects
Primary endpoint: Cycloplegic Refraction Change in SER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stuttering Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging parameter utility for pseudoprogression vs. true tumor growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance characteristics of the Septin 9 biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Willing to Try HRPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants That Completed 1-week Trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Willing to Continue With Preferred HRP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention in care 6 months post-transfer
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Retention in care 12 months post-transfer
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Retention in care 24 months post-transfer
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Compulsive Sexual Behavior (YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of low-level viremia (LLV) during ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequencies of persistent viremia (PV) after start of ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence or absence of mycoplasma hominis cultured from joint and wound fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patency of fistula as assessed by clinical exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain reduction as measured by pain scale and amount of pain medication required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working memory test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PYY response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ghrelin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CCK response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: motilin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IKS 2011 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with HBsAg ≤ 20,000 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with any decline of HBsAg and/or HBV DNA decline more than 2 log copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score Brody 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky Driving Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status